Patents Assigned to Trustees of Boston University
  • Publication number: 20180346541
    Abstract: Described herein is a chimeric antigen receptor (CAR) platform with the ability to (a) serve as an ON/OFF switch (with the ability for tenability/titrability), (b) sense multiple antigens and perform logic computations, and/or (c) independently regulate multiple signaling pathways. The compositions provided herein permit the degree of control and discrimination necessary to optimize CAR T cell therapy. Also described herein are cells comprising such compositions and the use of these compositions and/or cells in the treatment of cancer.
    Type: Application
    Filed: November 22, 2016
    Publication date: December 6, 2018
    Applicant: Trustees of Boston University
    Inventors: Wilson W. WONG, Jang Hwan CHO
  • Publication number: 20180346566
    Abstract: The technology described herein is directed to the diagnosis, prognosis, and treatment of conditions of the kidney, e.g., kidney cancer and/or kidney disease, and also relates to methods, compositions and kits comprising an agonist of the TMIGD1 (transmembrane and immunoglobulin containing 1) polypeptide.
    Type: Application
    Filed: May 19, 2016
    Publication date: December 6, 2018
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventor: Nader RAHIMI
  • Patent number: 10138493
    Abstract: Embodiments disclosed herein provide artificial expression systems comprising the zinc-finger containing transcription factors and engineered promoters to modulate expression of genes of interest. Engineered zinc-finger transcription factors that interact with engineered promoters constitute synthetic and regulatable expression systems which facilitate the modulation of gene expression as desired.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: November 27, 2018
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE GENERAL HOSPITAL CORPORATION
    Inventors: Ahmad S. Khalil, Divya Israni, Minhee Park, J. Keith Joung, Jeffry D. Sander
  • Publication number: 20180334731
    Abstract: Disclosed herein are shelf-stable compositions based on synthetic gene networks and/or cell-free systems that are lyophilized on a solid support. The compositions can be easily transported and stored for a period of time, and activation can be done by simply adding water. Methods of use are also disclosed herein, including, but are not limited to, sensing and a variety of logic functions. The invention permits straightforward, sterile and abiotic distribution of synthetic biology-based technology to clinical settings, food processing and industry, the military and consumer products.
    Type: Application
    Filed: April 26, 2018
    Publication date: November 22, 2018
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Keith Pardee, James J. Collins
  • Publication number: 20180328923
    Abstract: Provided herein are microorganisms engineered with hybrid receptors and genetic circuits. Also provided are hybrid receptors having a CqsS polypeptide and a heterologous histidine kinase domain of a two-component system. Methods for using engineered microorganisms to sense and destroy pathogens (e.g., Vibrio cholerae) are also provided.
    Type: Application
    Filed: June 9, 2016
    Publication date: November 15, 2018
    Applicants: Massachusetts Institute of Technology, Trustees of Boston University
    Inventors: Ning Mao, Douglas Ewen Cameron, James Collins
  • Publication number: 20180305703
    Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
    Type: Application
    Filed: March 16, 2018
    Publication date: October 25, 2018
    Applicants: Trustees of Boston University, Massachusetts Institute of Technology
    Inventors: Timothy Kuan-Ta Lu, Robert James Citorik, James Collins, Russell-John Krom
  • Publication number: 20180296722
    Abstract: The inventions provided herein relate to dissolvable hydrogel compositions and methods of uses, e.g., but not limited to, in wound management. Accordingly, methods for wound management involving the dissolvable hydrogel compositions are also provided herein. In some embodiments, the dissolvable hydrogel composition comprises an adhesive thioester hydrogel, which can facilitate adherence of the dissolvable hydrogen composition to a surface (e.g., a wound) and can be controllably dissolved later upon addition of a thiolate compound to release the dissolvable hydrogel composition from the surface (e.g., the wound).
    Type: Application
    Filed: May 9, 2018
    Publication date: October 18, 2018
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Mark W. GRINSTAFF, Cynthia GHOBRIL, Michel Christophe WATHIER, Marlena Dagmara KONIECZYNSKA
  • Publication number: 20180297976
    Abstract: Disclosed herein are reaction compositions comprising an oxidation catalyst, a solvent, and a substrate that is dissolved in the solvent. The oxidation catalyst comprises a metal ion complexed with an ?-keto acid and a tridentate N,N,O-ligand. Also disclosed herein are methods for oxidizing a C—H bond of a molecule, the methods comprising contacting the molecule with a metal complex comprising a metal ion complexed with a tridentate N,N,O-ligand in the presence of an ?-keto acid and a solvent. In some embodiments, the oxidation catalyst or metal complex is linked to a solid support.
    Type: Application
    Filed: December 18, 2015
    Publication date: October 18, 2018
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: John Philip CARADONNA, Paul C. TARVES, Joshua MCNALLY, Lauren GREGOR
  • Publication number: 20180296492
    Abstract: Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nanoparticles are endocytosed by the CD169+ expressing cells.
    Type: Application
    Filed: May 22, 2018
    Publication date: October 18, 2018
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Bjoern Markus Reinhard, Suryaram Gummuluru
  • Patent number: 10098967
    Abstract: Disclosed are conjugates of hydrophobic drugs linked to protected or unprotected amino acids or peptides. The disclosed conjugates are amphiphilic and can self assemble into nantubes. Nanotubes comprising the conjugates are also described and can have high loading of the drug and protect it from degradation or elimination. The nanotubes are well suited to deliver hydrophobic and unstable drugs to individuals.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: October 16, 2018
    Assignees: Ohio State Innovation Foundation, Trustees of Boston University
    Inventors: Jonathan R. Parquette, Se Hye Kim, Mark W. Grinstaff, Jonah A. Kaplan
  • Patent number: 10101315
    Abstract: Chemical functionalization of solid-state nanopores and nanopore arrays and applications thereof. Nanopores are extremely sensitive single-molecule sensors. Recently, electron beams have been used to fabricate synthetic nanopores in thin solid-state membranes with sub-nanometer resolution. A new class of chemically modified nanopore sensors are provided with two approaches for monolayer coating of nanopores by: (1) self-assembly from solution, in which nanopores ?10 nm diameter can be reproductibly coated, and (2) self-assembly under voltage-driven electrolyte flow, in which 5 nm nanopores may be coated. Applications of chemically modified nanopore are provided including: the detection of biopolymers such as DNA and RNA; immobilizing enzymes or other proteins for detection or for generating chemical gradients; and localized pH sensing.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 16, 2018
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Amit Meller, Meni Wanunu
  • Patent number: 10093979
    Abstract: Embodiments of the invention relate to single nucleotide polymorphisms (SNPs) in Thrombospondin 1 gene (THB-S1) that are herein linked to an increased risk for dry eye (also known as keratoconjunctivitis). The polymorphisms disclosed herein are directly useful for the diagnosis of an increased risk for dry eye, as well as for the determination of patient treatment pre- and post-surgery (e.g. pre and post refractive eye surgery) or in a patient having a condition associate with dry eye (e.g. diabetes, lupus, scleroderma, Sjogren's syndrome, thyroid disorders, vitamin A deficiency, and rheumatoid arthritis). Computer systems and medium are also enclosed. The SNPs can be present in unique combinations, or as specific haplotypes indicative of dry eye. The SNPs linked to an increased risk for dry eye include rs1478604, rs2228261, and rs2292305.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 9, 2018
    Assignee: Trustees of Boston University
    Inventor: Sharmila Masli
  • Publication number: 20180282813
    Abstract: Described herein are methods for the diagnosis, prognosis, and treatment of neurological conditions, e.g. Huntington's Disease, relating to the misregulation of miRNAs in such conditions.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 4, 2018
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Richard H. MYERS, Andrew HOSS, Vinay Krishna KARTHA
  • Patent number: 10087149
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that benefit from inhibition of HDAC8 activity.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: October 2, 2018
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Aaron Beaty Beeler, John A. Porco, Jr., Oscar J. Ingham, James E. Bradner
  • Patent number: 10085988
    Abstract: A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: October 2, 2018
    Assignees: SRI International, Trustees of Boston University
    Inventors: Tony Tianyi Wang, Shufeng Liu, Wenyu Wang, Neil Lajkiewicz, John A. Porco, Jr.
  • Patent number: 10090426
    Abstract: A photosensor device for reducing dark current is disclosed. The photosensor device includes a photon absorbing layer and two or more photosensor diffusions in said absorbing layer. The photosensor diffusions in the absorbing layer have edges of their diffusions separated in said absorbing layer by less than two minority carrier diffusion lengths. The photosensor device also includes in one embodiment one or more diffusion control junction diffusions in the absorbing layer and in proximity to the photosensor diffusions. In another embodiment the photosensor diffusions are selectively biased to operate as photosensor diodes or as diffusion impediments.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: October 2, 2018
    Assignee: Trustees of Boston University
    Inventors: Adam R. Wichman, Enrico Bellotti, Benjamin James Pinkie
  • Patent number: 10080766
    Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: September 25, 2018
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen
  • Publication number: 20180267065
    Abstract: Described herein are methods for measuring analytes, wherein a portion of the analyte in a sample is bound by a binding protein. In some embodiments, the methods relate to measuring vitamin D or metabolites thereof, e.g., vitamin D in samples also comprising a vitamin D binding protein.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 20, 2018
    Applicant: Trustees of Boston University
    Inventor: Michael Francis Holick
  • Patent number: 10076460
    Abstract: A method and wearable system and for enhancing human balance and gait and preventing foot injury through neurological stimulation of the foot and the ankle. Subthreshold stimulation for neurosensory enhancement is provided via electrodes or vibrational actuators, or combination thereof, disposed in or on a wearable a platform, such as an insole, sock shoe, removable shoe insert, or applied without the support of a platform, to the skin surface of an individual. Suprathreshold stimulation for therapeutic purposes, such as improving blood flow, is also provided by the vibrational actuators. The actuators and electrodes are driven by bias signals generated by a bias signal generator that is coupled to a controller. The signal generator under the control of the controller is adapted to generate a non-deterministic random signal, a repetitive pattern or series of patterns.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: September 18, 2018
    Assignee: Trustees of Boston University
    Inventors: Jason D. Harry, James J. Collins, James B. Niemi, Attila A. Priplata, Stephen J. Kleshinski
  • Publication number: 20180245075
    Abstract: Provided herein are engineered systems and methods for establishing DNA adenine methylation at specific genomic locations and using DNA adenine methylation as an artificial chemical “handle” on the genome. These systems and methods allow for placing the handle on specific genomic locations as well as molecular technologies to bind, spatially spread, and maintain the handle. The systems described herein comprise, in some embodiments, three functional modules that mediate m6A operations: (1) a synthetic initiator module to place m6A at specific genomic sites; (2) a synthetic readout module to program m6A recognition and m6A-dependent transcriptional logic; and (3) propagation module that implements “read-write,” a mechanism proposed to underlie chromatin spreading and epigenetic maintenance across cellular systems.
    Type: Application
    Filed: February 6, 2018
    Publication date: August 30, 2018
    Applicant: Trustees of Boston University
    Inventors: Ahmad S. KHALIL, Albert J. KEUNG, Minhee PARK